Galactose-Fucose Monosaccharide Composition for Re-Epithelialization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing wound and lesion treatments, including polysaccharides and growth factors, lack effective strategies to accelerate healing, minimize scarring, and enhance re-epithelialization, with monosaccharides like galactose and fucose being overlooked for their therapeutic potential due to assumptions about structural stability and enzymatic breakdown requirements.
Innovation Solution
A composition comprising galactose and fucose in monosaccharide form is used as a promotor of tissue re-epithelialization, administered topically or in various formulations to enhance cellular proliferation and healing, leveraging their natural occurrence and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polysaccharides are used for wound healing, then structural stability is maintained, but re-epithelialization promotion is insufficient
Solution Approach 1:
The patent segments the polysaccharide structure into individual monosaccharide units (galactose and fucose), allowing each unit to independently promote re-epithelialization while maintaining overall therapeutic effectiveness. This segmentation enables better absorption and cellular utilization compared to intact polysaccharides.
Solution Approach 2:
The patent changes the molecular size parameter from large polysaccharide molecules to small monosaccharide units, improving bioavailability and cellular uptake. This parameter change allows the substances to penetrate cell membranes more effectively and stimulate re-epithelialization without compromising safety.
2Productivity
If polysaccharides are broken down to monosaccharides, then re-epithelialization is enhanced, but structural stability is compromised
Solution Approach 1:
Instead of breaking down polysaccharides to monosaccharides and risking stability loss, the patent inverts the approach by directly using monosaccharides as the active therapeutic agents. This inversion eliminates the need for enzymatic breakdown in the wound site while maintaining structural integrity through the use of stable, naturally occurring monosaccharide molecules.
3Productivity
If growth factors and cytokines are used, then healing is accelerated, but complexity and cost increase
Solution Approach 1:
The patent uses simple, naturally occurring monosaccharides (galactose and fucose) that are inexpensive to produce and administer, replacing complex and costly growth factors and cytokines. These monosaccharides provide effective healing promotion without the complexity of protein-based therapies, making them more suitable for routine wound care applications.
4Reliability
If polysaccharides are used, then treatment is safe, but healing acceleration is limited
Solution Approach 1:
The patent changes the molecular parameter from large polysaccharide molecules to small monosaccharide units, improving cellular uptake and healing acceleration while maintaining safety. The monosaccharides are naturally occurring substances with well-established safety profiles, eliminating the need for extensive safety testing while achieving faster healing results.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed is a composition (204) comprising galactose and fucose in monosaccharide form for use as a promotor of tissue re-epithelialization.